Cargando…

The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

BACKGROUND: The aim of the present meta-analysis was to evaluate the effect of disease-modifying drugs (DMD) on brain atrophy in patients with relapsing-remitting multiple sclerosis (RRMS) using available randomized-controlled trial (RCT) data. METHODS: We conducted a systematic review and meta-anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsivgoulis, Georgios, Katsanos, Aristeidis H., Grigoriadis, Nikolaos, Hadjigeorgiou, Georgios M., Heliopoulos, Ioannis, Kilidireas, Constantinos, Voumvourakis, Konstantinos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355592/ https://www.ncbi.nlm.nih.gov/pubmed/25756363 http://dx.doi.org/10.1371/journal.pone.0116511

Ejemplares similares

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Tsivgoulis, Georgios, et al.
Publicado: (2015)

The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials
por: Tsivgoulis, Georgios, et al.
Publicado: (2016)

“Liberation treatment” for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free
por: Tsivgoulis, Georgios, et al.
Publicado: (2015)

Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece
por: Dardiotis, Efthymios, et al.
Publicado: (2022)

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options
por: Andravizou, Athina, et al.
Publicado: (2019)

Virus-mediated autoimmunity in Multiple Sclerosis
por: Grigoriadis, Nikolaos, et al.
Publicado: (2006)

Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
por: Chylińska, Magdalena, et al.
Publicado: (2023)

Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis
por: Meijboom, Rozanna, et al.
Publicado: (2023)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
por: Branger, Pierre, et al.
Publicado: (2016)

Regional gray matter atrophy and neuropsychologcal problems in relapsing-remitting multiple sclerosis
por: Lin, Aiyu, et al.
Publicado: (2013)

Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis
por: Efthymiou, Georgios, et al.
Publicado: (2017)

Sexual dysfunction therapeutic approaches in patients with multiple sclerosis: a systematic review
por: Giannopapas, Vasileios, et al.
Publicado: (2022)

Important advances in stroke research in 2020
por: Tsivgoulis, Georgios, et al.
Publicado: (2021)

Moyamoya Disease May Mimic Multiple Sclerosis?
por: Spanou, Ioanna, et al.
Publicado: (2019)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
por: Alkhawajah, Mona, et al.
Publicado: (2011)

Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study
por: Pantzaris, Marios C, et al.
Publicado: (2022)

Multiple Sclerosis: Shall We Target CD33?
por: Siokas, Vasileios, et al.
Publicado: (2020)

Regional Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: Baseline Analysis of Multi-Center Data
por: Datta, Sushmita, et al.
Publicado: (2015)

Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers
por: Bussas, Matthias, et al.
Publicado: (2021)

Serum Leptin Levels in Treatment-Naive Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
por: Evangelopoulos, Maria Eleftheria, et al.
Publicado: (2014)

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
por: Imani, Ali, et al.
Publicado: (2012)

Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Abdel-mannan, Omar A., et al.
Publicado: (2021)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
por: Boziki, Marina, et al.
Publicado: (2021)

The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

Cytokines as Biomarkers of Treatment Response to IFNβ in Relapsing-Remitting Multiple Sclerosis
por: Dimisianos, Nikolaos, et al.
Publicado: (2014)

Reperfusion Therapies of Acute Ischemic Stroke: Potentials and Failures
por: Tsivgoulis, Georgios, et al.
Publicado: (2014)

Association of Ultrasonographic Parameters with Subclinical White-Matter Hyperintensities in Hypertensive Patients
por: Heliopoulos, Ioannis, et al.
Publicado: (2012)

Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion
por: Psychogios, Klearchos, et al.
Publicado: (2021)

Relapsing Remitting Multiple Sclerosis in X-Linked Charcot-Marie-Tooth Disease with Central Nervous System Involvement
por: Koutsis, Georgios, et al.
Publicado: (2015)

Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study
por: Siokas, Vasileios, et al.
Publicado: (2021)

The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
por: Biolato, Marco, et al.
Publicado: (2021)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1a7lrhvukbkj39r7epblb3dc3i